Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)
AI disclosure
Summary
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.